EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Julian Panés  ¹     Anita Afzali  ²     David T. Rubin  ³     Bruce E. Sands  ⁴     Walter Reinisch  ⁵     Geert R. D'Haens  ⁶     Mario Gomez  ⁷     Natalie Terry  ⁸     Aparna Sahoo  ⁸     Mary Ellen Frustaci  ⁹     Zijiang Yang  ⁹     William Sandborn  ¹⁰     Remo Panaccione  ¹¹     Tadakazu Hisumatsu  ¹²     Silvio Danese  ¹³     Jane Andrews  ¹⁴     Brian G. Feagan  ^15    
1 Hospital Clínic Barcelona, Barcelona, Spain
² Ohio State University, Hilliard, United States
³ University of Chicago Medicine, Chicago, United States
⁴ Icahn School of Medicine at Mount Sinai, New York, United States
⁵ Medical University of Vienna, Vienna, Austria
⁶ AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
⁷ Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham
⁸ Janssen Research & Development, LLC, Spring House
⁹ Janssen Research and Development, LLC, Spring House, United States
¹⁰ University of California San Diego, La Jolla, United States
¹¹ University of Calgary, Calgary, Canada
¹² Kyorin University School of Medicine, Kyorin, Japan
¹³ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
¹⁴ Royal Adelaide Hospital, Adelaide, Australia
¹⁵ The University of Western Ontario, London, Canada

Session
Patient reported outcomes in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)